N. Galiè (Bologna (BO), Italy), O. Sitbon (Le Kremlin-Bicêtre, France)
This session is built from abstracts published on the ERS Congress platform from 23 August, in a PowerPoint format with a pre-recorded audio narration. The live session is scheduled from September 5-7 and each presenter will have a 5-minutes live, slide show presentation followed at the end of the session by 30-minutes general discussion.
PULSAR open-label extension: interim results from a phase 2 study of the efficacy and safety of sotatercept when added to standard of care for the treatment of pulmonary arterial hypertension (PAH) D. Badesch (Aurora, United States of America), S. Gibbs (London, United Kingdom), M. Gomberg-Maitland (Washington DC, United States of America), M. Hoeper (Hannover, Germany), V. Mclaughlin (Ann Arbor, United States of America), I. Preston (Boston, United States of America), R. Souza (São Paulo, Brazil), A. Waxman (Boston, United States of America), S. Manimaran (Cambridge, United States of America), J. Barnes (Cambridge, United States of America), J. De Oliveira Pena (Cambridge, United States of America), M. Humbert (Le Kremlin-Bicêtre, France), M. Hoeper (Hannover, Germany)
|    |
Risk stratification in patients with pulmonary arterial hypertension (PAH) and candidates for lung or heart-lung transplantation H. Vicaire (Le Kremlin-Bicêtre, France), J. Le Pavec (Le Plessis Robinson, France), A. Boucly (Le Kremlin-Bicêtre, France), X. Jais (Le Kremlin-Bicêtre, France), O. Mercier (Le Plessis Robinson, France), D. Montani (Le Kremlin-Bicêtre, France), E. Fadel (Le Plessis Robinson, France), M. Humbert (Le Plessis Robinson, France), O. Sitbon (Le Plessis Robinson, France), L. Savale (Le Kremlin-Bicêtre, France)
|    |
Lack of agreement between the exercise variables to assess the risk in PAH. A. Martinez Meñaca (Santander , Spain), V. Mora Cuesta (Santander, Spain), J. Cifrián Martínez (Santander , Spain), J. Barberá (Barcelona, Spain), M. López Meseguer (Barcelona, Spain), J. Domingo Morena (Zaragoza, Spain), J. Rueda Soriano, (Valencia, Spain), S. Alcolea (Madrid, Spain), F. Pastor Pérez (Murcia, Spain), P. Escribano Subias (Madrid, Spain)
|    |
Feasibility and Validation Testing of the Walk.Talk.Track. (WTT) App for Remote Monitoring of the Six Minute Walk Test (6MWT) in Pulmonary Arterial Hypertension (PAH). V. Glinskii (Stanford, United States of America), R. Anderson (Stanford, United States of America), A. Lopez (Stanford, United States of America), A. Lin (Stanford, United States of America), P. Del Rosario (Stanford, United States of America), S. Hershman (Stanford, United States of America), J. Hess (Burbank, United States of America), V. De Jesus Perez (Stanford, United States of America), R. Zamanian (Stanford, United States of America)
|    |
Dehydroepiandrosterone and GDF-15 for follow-up of patients with pulmonary arterial hypertension V. Foris (Graz, Austria), C. Mutgan (Graz, Austria), A. Borenich (Graz, Austria), G. Kovacs (Graz, Austria), P. Douschan (Graz, Austria), T. Sassmannn (Graz, Austria), K. Zeder (Graz, Austria), A. Olschewski (Graz, Austria), G. Kwapiszewska (Graz, Austria), H. Olschewski (Graz, Austria)
|    |
Pulmonary arterial hypertension in Adult-Onset Still’s Disease A. Boucly (Le Kremlin Bicètre, France), S. Mitrovic (Paris, France), L. Savale (Le Kremlin Bicètre, France), X. Jaïs (Le Kremlin Bicètre, France), D. Montani (Le Kremlin Bicètre, France), E. Lazaro (Pessac, France), N. Schleinitz (Marseille, France), C. Bloch-Queyrat (Bobigny, France), C. Christides (Avignon, France), J. Pouchot (Paris, France), M. Humbert (Le Kremlin Bicètre, France), B. Fautrel (Paris, France), O. Sitbon (Le Kremlin Bicètre, France)
|    |
Association between Leflunomide and Pulmonary Hypertension T. Lacoste Palasset (Le Kremlin Bicêtre, France), M. Chaumais (Le Kremlin Bicêtre, France), J. Weatherald (Calgary, Canada), L. Savale (Le Kremlin Bicêtre, France), X. Jaïs (Le Kremlin Bicêtre, France), L. Price (London, United Kingdom), C. Khouri (Grenoble, France), S. Bulifon (Le Kremlin Bicêtre, France), A. Seferian (Le Kremlin Bicêtre, France), M. Jevnikar (Le Kremlin Bicêtre, France), A. Boucly (Le Kremlin Bicêtre, France), G. Manaud (Le Plessis-Robinson, France), S. Pancic (Calgary, France), C. Chabanne (Rennes, France), K. Ahmad (Lyon, France), M. Volpato (Montpellier, France), N. Favrolt (Dijon, France), A. Guillaumot (Vandoeuvre-lès-Nancy, France), D. Horeau-Langlard (Nantes, France), G. Prévot (Toulouse, France), P. Fesler (Montpellier, France), L. Bertoletti (Saint-Etienne, France), M. Reynaud-Gaubert (Marseille, France), N. Lamblin (Lille, France), D. Launay (Lille, France), G. Simonneau (Le Kremlin Bicêtre, France), O. Sitbon (Le Kremlin Bicêtre, France), F. Perros (Le Plessis-Robinson, France), M. Humbert (Le Kremlin Bicêtre, France), D. Montani (Le Kremlin Bicêtre, France)
|    |
Pregnancy in pulmonary arterial hypertension: mid-term outcomes of mothers and offspring J. Kamp (Hannover, Germany), C. Von Kaisenberg (Hannover, Germany), S. Greve (Hannover, Germany), L. Winter (Hannover, Germany), D. Park (Hannover, Germany), J. Fuge (Hannover, Germany), C. Kühn (Hannover, Germany), M. Hoeper (Hannover, Germany), K. Olsson (Hannover, Germany)
|    |
Favorable pregnancy outcomes in women with predominantly mild pulmonary arterial hypertension N. Corbach (Zürich, Switzerland), M. Lichtblau (Zürich, Switzerland), E. Schwarz (Zürich, Switzerland), F. Gautschi (Zürich, Switzerland), A. Groth (Zürich, Switzerland), R. Schüpbach (Zürich, Switzerland), F. Krähenmann (Zürich, Switzerland), S. Saxer (Zürich, Switzerland), S. Ulrich (Zürich, Switzerland)
|    |
Late Breaking Abstract - Convergence of clinical and computational phenotypes for rare variant association study (RVAS) in pulmonary arterial hypertension E. Swietlik (Cambridge, United Kingdom), D. Greene (Cambridge, United Kingdom), K. Auckland (Cambridge, United Kingdom), T. Tilly (Cambridge, United Kingdom), J. Martin (Cambridge, United Kingdom), N. Translational Research (Cambridge, United Kingdom), N. Morrell (Cambridge, United Kingdom), S. Gräf (Cambridge, United Kingdom)
|    |
Discussion
|  |